BioPharma Dive March 3, 2025
Gwendolyn Wu

Callio Therapeutics is debuting with an ADC technology and related programs licensed from Singapore-based antibody drug developer Hummingbird Bioscience.

Dive Brief:

  • Callio Therapeutics on Monday launched with $187 million in Series A funding and a license to a technology that can make antibody-drug conjugates, or ADCs, with multiple tumor-killing payloads.
  • The startup’s ADC capabilities come via a deal with Hummingbird Bioscience, a Singapore-based antibody specialist. Hummingbird granted Callio an exclusive license to use its “multi-payload” ADC technology in oncology. In return, Hummingbird received equity in Callio and could get additional milestone payments.
  • Headquartered in Seattle and Singapore, Callio was launched by Frazier Life Sciences. Its Series A was led by Frazier and involved nine other investors, among them Jeito...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

Continue Reading

 
Topics: Biotechnology, Investments, Pharma / Biotech, Trends
Related Articles:
Pharma Pulse 3/3/25: Will Tariffs Affect Branded Drug Prices? Pharmacists' Role in Medical Cannabis Counseling and Patient Education & more
Pharma’s Role in Ensuring Patient Access to Trustworthy Health Insights
AbbVie Enters Obesity Field, Paying $350M for Amylin Receptor Agonist Already in the Clinic
How Pharmaceutical Companies Can Mitigate a Potential Drop in Demand Due to Tariffs
State Licensing Spotlight - Prescription medical device manufacturers & distributors: Regulatory considerations applicable to medical devices versus drugs

Share This Article